Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $370 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $370.
October 17, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $370.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Vertex Pharmaceuticals. The maintained price target of $370 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100